Y. Miki, J. Swensen, D. Shattuck-eidens, P. Futreal, K. Harshman et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, vol.266, issue.5182, pp.66-71, 1994.
DOI : 10.1126/science.7545954

R. Wooster, S. Neuhausen, J. Mangion, Y. Quirk, D. Ford et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, Science, vol.265, issue.5181, pp.2088-90, 1994.
DOI : 10.1126/science.8091231

N. Mavaddat, A. Antoniou, D. Easton, and M. Garcia-closas, Genetic susceptibility to breast cancer, Molecular Oncology, vol.41, issue.3, pp.174-91, 2010.
DOI : 10.1038/ng.318

J. Hernández, M. Llacuachaqui, G. Palacio, J. Figueroa, J. Madrid et al., Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia. Hered Cancer Clin Pract, p.11, 2014.

D. Easton, P. Pharoah, A. Antoniou, M. Tischkowitz, S. Tavtigian et al., Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk, New England Journal of Medicine, vol.372, issue.23, pp.2243-57, 2015.
DOI : 10.1056/NEJMsr1501341

L. Melchor and J. Benítez, The complex genetic landscape of familial breast cancer, Human Genetics, vol.134, issue.3, pp.845-63, 2013.
DOI : 10.1007/s10549-012-2141-2

K. Michailidou, J. Beesley, S. Lindstrom, S. Canisius, J. Dennis et al., Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer, Nature Genetics, vol.490, issue.4, pp.373-80, 2015.
DOI : 10.1038/nature11412

L. Dorling, G. Barnett, K. Michailidou, C. Coles, N. Burnet et al., Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity, Clinical Cancer Research, vol.22, issue.6
DOI : 10.1158/1078-0432.CCR-15-1080

E. Rakha, Pitfalls in outcome prediction of breast cancer: Table??1, Journal of Clinical Pathology, vol.17, issue.Suppl 10, pp.458-64, 2013.
DOI : 10.1093/annonc/mdl238

W. Jacot, M. Gutowski, D. Azria, and G. Romieu, Adjuvant early breast cancer systemic therapies according to daily used technologies, Critical Reviews in Oncology/Hematology, vol.82, issue.3, pp.361-370, 2012.
DOI : 10.1016/j.critrevonc.2011.09.002

M. Martín, G. Palacios, F. Cortés, J. De-la-haba, J. Schneider et al., Prognostic and predictive factors and genetic analysis of early breast cancer, Clinical and Translational Oncology, vol.20, issue.[Suppl], pp.634-676, 2009.
DOI : 10.1016/S1699-8855(09)70147-3

A. Goldhirsch, E. Winer, A. Coates, R. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, issue.9, pp.2206-2229, 2013.
DOI : 10.1093/annonc/mdt303

S. Mccutcheon and F. Cardoso, Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference, The Breast, vol.24, issue.5, pp.623-632, 2015.
DOI : 10.1016/j.breast.2015.06.008

G. Hortobagyi, Trastuzumab in the Treatment of Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1734-1740, 2005.
DOI : 10.1056/NEJMe058196

W. Foulkes, I. Smith, and J. Reis-filho, Triple-Negative Breast Cancer, New England Journal of Medicine, vol.363, issue.20, pp.1938-1986, 2010.
DOI : 10.1056/NEJMra1001389

F. Ades, D. Zardavas, I. Bozovic-spasojevic, L. Pugliano, D. Fumagalli et al., Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives, Journal of Clinical Oncology, vol.32, issue.25, pp.2794-803, 2014.
DOI : 10.1200/JCO.2013.54.1870

X. Pivot, G. Romieu, M. Debled, J. Pierga, P. Kerbrat et al., 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.8, pp.741-749, 2013.
DOI : 10.1016/S1470-2045(13)70225-0

S. Gourgou-bourgade, D. Cameron, P. Poortmans, B. Asselain, D. Azria et al., Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of

P. Fasching, P. Pharoah, A. Cox, H. Nevanlinna, S. Bojesen et al., The role of genetic breast cancer susceptibility variants as prognostic factors, Human Molecular Genetics, vol.21, issue.17, pp.3926-3965, 2012.
DOI : 10.1093/hmg/dds159

J. Marcus, P. Watson, D. Page, S. Narod, G. Lenoir et al., Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage, Cancer, vol.76, issue.4, pp.697-709, 1996.
DOI : 10.1002/1097-0142(19950915)76:6<1009::AID-CNCR2820760615>3.0.CO;2-8
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W/pdf

D. Gaffney, R. Brohet, C. Lewis, J. Holden, S. Buys et al., Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations, Radiotherapy and Oncology, vol.47, issue.2, pp.129-165, 1998.
DOI : 10.1016/S0167-8140(98)00023-1

M. Robson, Are BRCA1-and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, pp.113-121, 2000.

A. Van-den-broek, M. Schmidt, L. Veer, R. Tollenaar, and F. Van-leeuwen, Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis, PLOS ONE, vol.5, issue.3, p.120189, 2015.
DOI : 10.1371/journal.pone.0120189.s013

P. Goodwin, K. Phillips, D. West, M. Ennis, J. Hopper et al., Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study, Journal of Clinical Oncology, vol.30, issue.1, pp.19-26, 2012.
DOI : 10.1200/JCO.2010.33.0068

D. Roukos, Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations, N Engl J Med, vol.357, pp.1555-1561, 2007.

Z. Baretta, S. Mocellin, E. Goldin, O. Olopade, and D. Huo, Effect of BRCA germline mutations on breast cancer prognosis, Medicine, vol.95, issue.40, p.4975, 2016.
DOI : 10.1097/MD.0000000000004975

X. Zhang, X. Shu, Q. Cai, Z. Ruan, Y. Gao et al., Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival, Clinical Cancer Research, vol.12, issue.20, pp.6037-6079, 2006.
DOI : 10.1158/1078-0432.CCR-05-2851

X. Shu, J. Long, W. Lu, C. Li, W. Chen et al., Novel Genetic Markers of Breast Cancer Survival Identified by a Genome-Wide Association Study, Cancer Research, vol.72, issue.5, pp.1182-1191, 2012.
DOI : 10.1158/0008-5472.CAN-11-2561

H. Lu, X. Shu, Y. Cui, N. Kataoka, W. Wen et al., Gene with Breast Cancer Survival, Cancer Research, vol.65, issue.12, pp.5015-5024, 2005.
DOI : 10.1158/0008-5472.CAN-04-2786

T. Toyama, Z. Zhang, M. Nishio, M. Hamaguchi, N. Kondo et al., Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients, Breast Cancer Research, vol.12, issue.3, p.34, 2007.
DOI : 10.3748/wjg.v12.i40.6536

M. Bewick, M. Conlon, and R. Lafrenie, and Survival After Treatment for Metastatic Breast Cancer, Journal of Clinical Oncology, vol.24, issue.36, pp.5645-51, 2006.
DOI : 10.1200/JCO.2006.05.9923

S. Rafiq, W. Tapper, A. Collins, S. Khan, I. Politopoulos et al., Identification of Inherited Genetic Variations Influencing Prognosis in Early-Onset Breast Cancer, Cancer Research, vol.73, issue.6, pp.1883-91, 2013.
DOI : 10.1158/0008-5472.CAN-12-3377

S. Rafiq, S. Khan, W. Tapper, A. Collins, R. Upstill-goddard et al., A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis, PLoS ONE, vol.45, issue.12, p.101488, 2014.
DOI : 10.1371/journal.pone.0101488.s001

S. Bayraktar, P. Thompson, S. Yoo, K. Do, A. Sahin et al., The Relationship Between Eight GWAS-Identified Single-Nucleotide Polymorphisms and Primary Breast Cancer Outcomes, The Oncologist, vol.18, issue.5, pp.493-500, 2013.
DOI : 10.1634/theoncologist.2012-0419
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662839

A. Pirie, Q. Guo, P. Kraft, S. Canisius, D. Eccles et al., Common germline polymorphisms associated with breast cancer-specific survival, Breast Cancer Research, vol.6, issue.1, p.58, 2015.
DOI : 10.1186/1471-2407-6-257
URL : http://doi.org/10.1186/s13058-015-0570-7

A. Woltmann, B. Chen, J. Lascorz, R. Johansson, J. Eyfjörd et al., Systematic Pathway Enrichment Analysis of a Genome-Wide Association Study on Breast Cancer Survival Reveals an Influence of Genes Involved in Cell Adhesion and Calcium Signaling on the Patients??? Clinical Outcome, PLoS ONE, vol.21, issue.6, p.98229, 2014.
DOI : 10.1371/journal.pone.0098229.s016

E. Azzato, P. Pharoah, P. Harrington, D. Easton, D. Greenberg et al., A Genome-Wide Association Study of Prognosis in Breast Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.19, issue.4, pp.1140-1143, 2010.
DOI : 10.1158/1055-9965.EPI-10-0085

N. Eriksson, G. Benton, C. Do, A. Kiefer, J. Mountain et al., Genetic variants associated with breast size also influence breast cancer risk, BMC Medical Genetics, vol.42, issue.5, 2012.
DOI : 10.1038/ng.686
URL : http://doi.org/10.1186/1471-2350-13-53

K. Purrington, S. Slettedahl, M. Bolla, K. Michailidou, K. Czene et al., Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade, Human Molecular Genetics, vol.23, issue.22, pp.6034-6080, 2014.
DOI : 10.1093/hmg/ddu300
URL : https://academic.oup.com/hmg/article-pdf/23/22/6034/17260728/ddu300.pdf

. Investigators, . Nbcs-investigators, A. Pirie, Q. Guo, P. Kraft et al., Common germline polymorphisms associated with breast cancerspecific survival Available from: http://breast-cancer-research, Breast Cancer Res. [Internet], vol.17171, p.201558

K. Kiyotani, T. Mushiroda, T. Tsunoda, T. Morizono, N. Hosono et al., A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese, Human Molecular Genetics, vol.21, issue.7, pp.1665-72, 2012.
DOI : 10.1093/hmg/ddr597

Q. Guo, M. Schmidt, P. Kraft, S. Canisius, C. Chen et al., Identification of Novel Genetic Markers of Breast Cancer Survival, JNCI: Journal of the National Cancer Institute, vol.107, issue.5, p.81, 2015.
DOI : 10.1093/jnci/djv081

A. Broeks, M. Schmidt, M. Sherman, F. Couch, J. Hopper et al., Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium, Human Molecular Genetics, vol.20, issue.16, pp.3289-303, 2011.
DOI : 10.1093/hmg/ddr228

D. Cox, E. Curtit, G. Romieu, P. Fumoleau, M. Rios et al., GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the <i>FGFR2</i> locus and estrogen receptor status to HER2-negative breast cancer patients, Oncotarget, vol.7, pp.77358-64, 2016.
DOI : 10.18632/oncotarget.12669

S. Paik, G. Tang, S. Shak, C. Kim, J. Baker et al., Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3760, 2006.
DOI : 10.1200/JCO.2005.04.7985

C. Kelly, E. Warner, D. Tsoi, S. Verma, and K. Pritchard, Review of the Clinical Studies Using the 21-Gene Assay, The Oncologist, vol.15, issue.5, pp.447-56, 2010.
DOI : 10.1634/theoncologist.2009-0277

J. Gligorov, X. Pivot, W. Jacot, H. Naman, D. Spaeth et al., Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study, The Oncologist, vol.20, issue.8, pp.873-882, 2015.
DOI : 10.1634/theoncologist.2014-0467

F. Cardoso, . Van-'t, L. Veer, J. Bogaerts, L. Slaets et al., 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, New England Journal of Medicine, vol.375, issue.8, pp.717-746, 2016.
DOI : 10.1056/NEJMoa1602253

E. Curtit, L. Mansi, Y. Maisonnette-escot, J. Sautière, and X. Pivot, Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX ?? Breast Recurrence Score Assay, European Journal of Surgical Oncology (EJSO), vol.43, issue.5, pp.921-951, 2017.
DOI : 10.1016/j.ejso.2016.11.016

P. Pharoah, A. Antoniou, D. Easton, and B. Ponder, Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer, New England Journal of Medicine, vol.358, issue.26, pp.2796-803, 2008.
DOI : 10.1056/NEJMsa0708739

M. Barrdahl, F. Canzian, S. Lindström, I. Shui, A. Black et al., with breast cancer survival, International Journal of Cancer, vol.33, issue.12, pp.2837-2882, 2015.
DOI : 10.1002/humu.22089